Holen, I., Neville-Webbe, H. and Coleman, R.E. (2006) Benefits of combined treatments using antiresorptive agents and cytotoxic drugs. In: Breast cancer research: the past and the future, 1 November 2006, London, UK.
Breast cancer patients often receive a combination of different therapies, but our understanding of how best to utilise such combinations to achieve maximal benefit for the patients is incomplete. We have investigated the ability of the antiresorptive agent zoledronic acid (Zol) and the commonly used chemotherapy agents paclitaxel (Pac) and doxorubicin (Dox) to induce apoptotic breast cancer cell death in vitro.
|Copyright, Publisher and Additional Information:||© 2006 BioMed Central Ltd|
|Institution:||The University of Sheffield|
|Academic Units:||The University of Sheffield > Faculty of Science (Sheffield) > School of Biological Sciences (Sheffield) > Department of Biomedical Science (Sheffield)
The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield)
|Depositing User:||Sheffield Import|
|Date Deposited:||05 Oct 2009 11:06|
|Last Modified:||08 Oct 2009 10:09|